Ionis Adds Former Grail Chief Commercial Officer to Executive Team

Ionis Pharmaceuticals (NASDAQ: [[ticker:IONS]]) appointed Onaiza Cadoret-Manier as its chief corporate development and commercial officer, a newly created position.

Cadoret-Manier was most recently chief commercial officer at Grail, a Menlo Park, CA-based startup spun out from Illumina (NASDAQ: [[ticker:ILMN]]) that is working to develop tests to detect cancer at its earliest stages. She was previously vice president of Genentech’s respiratory business. Prior experience includes roles at Pfizer (NYSE: [[ticker:PFE]]) and Amylin Pharmaceuticals, since acquired by Bristol-Myers Squibb (NYSE: [[ticker:BMY]]).

Carlsbad, CA-based Ionis, a developer of RNA-targeted therapeutics, is in the midst of a leadership transition. Founder and CEO Stanley Crooke made a planned transition this month from the top role to that of executive chairman. He was succeeded by Brett Monia, also a founder, who previously served as chief operating officer.

Author: Sarah de Crescenzo

Sarah is Xconomy's San Diego-based editor. Prior to joining the team in 2018, she wrote about startups, tech and finance at the San Diego Business Journal. Her decade of full-time news experience includes coverage of subjects including campaign finance, crime and courts as a reporter and editor at outlets throughout California, including the Orange County Register. She earned a bachelor's degree in English Literature at UC San Diego, where she wrote for the student newspaper and played collegiate lacrosse. In 2019, she earned an MBA at UC Irvine.